Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
+2.64 (2.33%)
Pre-market: 116.09 +0.38 (0.33%)
Jul 30, 8:11AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 115.11 - 119.46
52 week 85.95 - 123.37
Open 118.38
Vol / Avg. 6,167.00/10.44M
Mkt cap 166.17B
P/E 13.14
Div/yield 0.43/1.49
EPS 8.80
Shares 1.47B
Beta 0.69
Inst. own 86%
Oct 26, 2015
Q3 2015 Gilead Sciences Inc Earnings Release (Estimated) - 4:05PM EDT - Add to calendar
Jul 28, 2015
Q2 2015 Gilead Sciences Inc Earnings Call - Webcast
Jul 28, 2015
Q2 2015 Gilead Sciences Inc Earnings Release
Jun 9, 2015
Gilead Sciences Inc at Goldman Sachs Healthcare Conference
Jun 9, 2015
Gilead Sciences Inc at William Blair Annual Growth Stock Conference
May 28, 2015
Gilead Sciences Inc at Sanford C Bernstein Strategic Decisions Conference
May 19, 2015
Gilead Sciences Inc at UBS Global Healthcare Conference
May 13, 2015
Gilead Sciences Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Gilead Sciences Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 57.05% 48.45%
Operating margin 70.73% 61.33%
EBITD margin - 65.55%
Return on average assets 47.61% 42.13%
Return on average equity 106.60% 90.32%
Employees 7,000 -
CDP Score - -


United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Brett Pletcher Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul Rutherford Carter Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Andrew Cheng M.D., Ph.D. Executive Vice President - HIV Therapeutics and Development Operations
Bio & Compensation  - Reuters
William A. Lee Ph.D. Executive Vice President - Research
Age: 56
Bio & Compensation  - Reuters
Taiyin Yang Ph.D. Executive Vice President - Pharmaceutical Development and Manufacturing
Age: 60
Bio & Compensation  - Reuters